Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002886634 | SCV003254455 | uncertain significance | Cranioectodermal dysplasia 1 | 2022-06-23 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 1215 of the IFT122 protein (p.Val1215Met). This variant is present in population databases (rs139940512, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with IFT122-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV002886634 | SCV003813243 | uncertain significance | Cranioectodermal dysplasia 1 | 2021-05-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004066184 | SCV004885922 | uncertain significance | Inborn genetic diseases | 2023-10-13 | criteria provided, single submitter | clinical testing | The c.3643G>A (p.V1215M) alteration is located in exon 30 (coding exon 30) of the IFT122 gene. This alteration results from a G to A substitution at nucleotide position 3643, causing the valine (V) at amino acid position 1215 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |